The green light for Pfizer’s Covid vaccine for children aged 5 to 11 in the US could arrive by winter. Reporting to the ‘CNBC’ is Scott Gottlieb, a member of the Pfizer board and former head of the US FDA. “If the Food and Drug Administration sticks to its normal schedule – explained the expert in an interview – we would expect the review to be 4-6 weeks for a potential emergency use authorization”, and this would place the verdict “in a timeline” which is “late autumn, early winter”.
This considered that the company’s vaccine study data for this age group “should be available in September” and then submitted to the FDA in the same month. And that “the application will probably not be presented until some point in October”.